[
  {
    "ts": null,
    "headline": "GILD's Investigational Regimen for HIV Treatment Meets Primary Goal",
    "summary": "Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.",
    "url": "https://finnhub.io/api/news?id=ceb3f72f222142ac665990caf14e64ada95796f158b71710c287283a5b8cc8a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125860,
      "headline": "GILD's Investigational Regimen for HIV Treatment Meets Primary Goal",
      "id": 137480395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.",
      "url": "https://finnhub.io/api/news?id=ceb3f72f222142ac665990caf14e64ada95796f158b71710c287283a5b8cc8a0"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD?",
    "summary": "Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV regimen combining bictegravir and lenacapavir, confirming non-inferiority versus multi-tablet therapy and reporting a favorable safety profile. This development highlights Gilead’s continued progress in simplifying treatment for people living with HIV and advancing next-generation regimens that address patient needs for convenience and tolerability. We’ll examine how...",
    "url": "https://finnhub.io/api/news?id=c75d715287c54aa0f2a078b2cf826618725d279c16a445ef56cc4dac8571d8da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763122569,
      "headline": "Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD?",
      "id": 137480396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV regimen combining bictegravir and lenacapavir, confirming non-inferiority versus multi-tablet therapy and reporting a favorable safety profile. This development highlights Gilead’s continued progress in simplifying treatment for people living with HIV and advancing next-generation regimens that address patient needs for convenience and tolerability. We’ll examine how...",
      "url": "https://finnhub.io/api/news?id=c75d715287c54aa0f2a078b2cf826618725d279c16a445ef56cc4dac8571d8da"
    }
  },
  {
    "ts": null,
    "headline": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
    "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
    "url": "https://finnhub.io/api/news?id=9ee3a50118c6b40265a7f5262ca803264af8472d394819571c2dcb0fc3faf3f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763118360,
      "headline": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
      "id": 137480397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
      "url": "https://finnhub.io/api/news?id=9ee3a50118c6b40265a7f5262ca803264af8472d394819571c2dcb0fc3faf3f5"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Own for Decades and 2 We Avoid",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 11.6% has lagged the S&P 500’s 16.3% climb.",
    "url": "https://finnhub.io/api/news?id=d18bee16e96f84b00e5990a016d377a6ca9f3c6e474b811c6a47950c85d6f610",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763095308,
      "headline": "1 Healthcare Stock to Own for Decades and 2 We Avoid",
      "id": 137478325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 11.6% has lagged the S&P 500’s 16.3% climb.",
      "url": "https://finnhub.io/api/news?id=d18bee16e96f84b00e5990a016d377a6ca9f3c6e474b811c6a47950c85d6f610"
    }
  }
]